GlobeNewsWire
07 Nov 2025, 12:30 UTC · 48w ago
Verdict
Headline takes no side. We score CNTX +0.40 across three claims — moderately bullish.
+0.40moderately bullish
More positive than 70% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Context Therapeutics expects to provide initial Phase 1a data for its CT-95 program in the middle of 2026.
So whatClinical data readouts are the primary catalysts for biotech valuations, though the distant timeline limits immediate impact.
More positive than 80% of claims this week
The company expects to complete regulatory filings to initiate a first-in-human trial for CT-202 in the second quarter of 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 68% of claims this week
Context Therapeutics presented posters on its CT-95 and CT-202 T cell engaging bispecific antibody programs at the 2025 SITC Annual Meeting.
More positive than 47% of claims this week
Which stocks this story touches
More positive than 70% of ticker scores this week
The company is presenting progress and highlighting milestones for its CT-95 and CT-202 oncology programs at a major industry conference.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Barrons
22h ago
−76.1%
Price is moving against the score
$0.2556 vs $1.07 close before publication (Nov 6) · not market-adjusted
CNTX chart →
